This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Oct 2011

Allon Completes Patient Enrolment for Davunetide Phase II/III Trial

Allon Therapeutics has announced its completion of the enrollment objective of 300 patients in the phase 2/3 pivotal clinical trial evaluating the neuroprotective drug candidate Davunetide.

Vancouver-based biotechnology company Allon Therapeutics has completed the enrolment of 300 patients in a Phase II/III pivotal trial to evaluate neuroprotective drug candidate Davunetide as a treatment for progressive supranuclear palsy, a rapidly progressing and fatal degenerative brain disease.


Davunetide is derived from a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein.


Earlier human clinical and pre-clinical data suggested that Davunetide has shown significant impacts on memory, activities of daily living, and a biomarker of brain cell function and integrity.


The Phase II/III trial is being conducted under

Related News